Solid organ transplant in recipients with ongoing SARS-CoV-2 infection: A systematic review of case reports and series

•Deliberate SOT of recipients with ongoing SARS-CoV-2 is performed worldwide.•Recipients are fit, immunized against the virus, displaying a nonsevere disease.•No COVID-19-related deaths were recorded.•The exclusion of these patients from transplantation should be reviewed. Whether solid organ transp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of infectious diseases Jg. 147; S. 107214
Hauptverfasser: Lombardi, Andrea, Colaneri, Marta, Azzarà, Cecilia, Saltini, Paola, Viero, Giulia, Palomba, Emanuele, Biscarini, Simona, Gori, Andrea, Bandera, Alessandra
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Canada Elsevier Ltd 01.10.2024
Elsevier
Schlagworte:
Covid-19
Recipient
Sars-cov-2
Solid organ transplant
Sars-cov-2
Ct
Covid-19
SOT
Recipient
Solid organ transplant
PCR
ISSN:1201-9712, 1878-3511, 1878-3511
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Deliberate SOT of recipients with ongoing SARS-CoV-2 is performed worldwide.•Recipients are fit, immunized against the virus, displaying a nonsevere disease.•No COVID-19-related deaths were recorded.•The exclusion of these patients from transplantation should be reviewed. Whether solid organ transplant (SOT) can be safely performed in recipients with ongoing SARS-CoV-2 infection is still a debated question. A systematic review of the literature on recipients with ongoing SARS-CoV-2 infection at the time of surgery and the associated outcomes. From 29 studies, we identified 54 recipients; their median age was 47.5 years, and over half (23/54, 54.85%) were affected by fewer than two comorbidities. Kidney was the most common transplanted organ (24/54, 44.4%). SOT was performed without knowing the ongoing infection in 11.1% (6/54) of patients. On average, 16.1 (SD 23.2) days elapsed between SARS-CoV-2 infection and SOT, with a mean Ct value at diagnosis and transplantation of 29 and 31.9, respectively. Most patients (25/39,64.1%) had received previous COVID-19 vaccinations. Twenty-four patients (45.3%) received an anti-SARS-CoV-2 therapy. Ten patients (18.5%) required oxygen support, while seven (13.7%) were admitted to the intensive care unit. There were two reported cases (3.7%) of all-cause death, while there were no cases of COVID-19-related death. Deliberate SOT of recipients with ongoing SARS-CoV-2 is performed worldwide in candidates of nonlung transplant who are fit, immunized against the virus, and displaying a nonsevere disease course. No COVID-19-related deaths were recorded. [Display omitted]
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1201-9712
1878-3511
1878-3511
DOI:10.1016/j.ijid.2024.107214